Login to Your Account



Restructuring Popular Strategy As Market, Investors Apply Pressure

By Randall Osborne


Monday, August 26, 2002

When flailing giant Elan Corp. plc made known its plan to restructure at the end of last month, tremors were felt worldwide. The Securities and Exchange Commission had raised questions about off-balance-sheet accounting procedures related to Elan's joint ventures, of which the company has no less than 55, and there had been shareholder lawsuits along with the more ordinary kind of problems, such as the suspension of clinical dosing of the Alzheimer's drug partnered with Wyeth-Ayerst Laboratories. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription